Sarpogrelate hydrochloride

Oral
Chronic arterial occlusion

Haemorrhage, including gastrointestinal ulceration, urinary tract haemorrhage, haemophilia, capillary fragility, haemoptysis, vitreous haemorrhage. Pregnancy.

Patient with haemorrhagic diathesis, bleeding tendency (e.g. gastrointestinal ulcer, haemoptysis, urinary tract haemorrhage, vitreous haemorrhage),or menstrual period. Severe renal impairment. Elderly. Lactation.

Significant: Cerebral and gastrointestinal haemorrhage, thrombocytopenia, agranulocytosis, jaundice, increased AST/ALT and bilirubin.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Palpitations, breath shortness, chest pain.
Gastrointestinal disorders: Abdominal pain, nausea, heartburn, constipation, anorexia, diarrhoea.
General disorders and administration site conditions: Malaise.
Investigations: Increased blood triglycerides and cholesterol, decreased serum albumin and serum calcium, increased weight.
Metabolism and nutrition disorders: Oedema.
Nervous system disorders: Headache, dizziness, taste abnormality.
Psychiatric disorders: Sleepiness.
Renal and urinary disorders: Proteinuria, increased BUN and creatinine, urinary sugar, abnormal urinary sediment.
Respiratory, thoracic and mediastinal disorders: Epistaxis.
Skin and subcutaneous tissue disorders: Rash, redness, pruritus.
Vascular disorders: Hot flush.

Monitor for abnormal haemorrhage and LFT.

Increased risk of bleeding with anticoagulants (e.g. warfarin) and antiplatelets (e.g. cilostazol, aspirin, ticlodipine).

Description:
Mechanism of Action: Sarpogrelate hydrochloride inhibits platelet aggregation and vascular contraction through antagonistic action to 5-HT₂ serotonin receptor in platelets and vascular smooth muscle thereby preventing blood clot formation and improving blood flow.
Pharmacokinetics:
Metabolism: Deesterified and further metabolised by multiple CYP enzymes (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4).
Excretion: Via urine (44.5%) and faeces (4.2%).

Source: National Center for Biotechnology Information. PubChem Database. Sarpogrelate hydrochloride, CID=444005, https://pubchem.ncbi.nlm.nih.gov/compound/Sarpogrelate-hydrochloride (accessed on Jan. 23, 2020)

Store between 20-25°C. Protect from light and moisture.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

Buckingham R (ed). Sarpogrelate Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/05/2018 .